Sushmita Panda is a New Delhi-based journalist with over six years of experience covering the healthcare and pharmaceutical sectors. She has reported on critical issues including drug patents and discovery, rare diseases, innovative therapies, women’s health, Neglected Tropical Diseases (NTDs), mental health, drug access, and regulatory affairs. Over the years, she has authored numerous in-depth stories and on-ground reports on diseases prevalent in India, including several exclusives and interviews with industry leaders. An alumna of the Asian College of Journalism and the University of Delhi, Sushmita has worked with national and international publications such as Financial Express, Sputnik, The Sunday Guardian, and India TV. When she’s not chasing stories, she enjoys reading and exploring new places.
Latest from Sushmita Panda
With Phase III plans underway and Part B data from its APEX trial due in 2026, Apogee is banking on zumilokibart's extended dosing advantage compared with rivals.
The deal, which is expected to close in the first half of 2026, includes $2bn upfront plus $1bn in milestone related payments.
Near-term focus for Rhythm will be on the upcoming regulatory decision for Imcivree in acquired hypothalamic obesity, with an FDA decision expected in the coming days.
The proceeds will help advance development of R1's AP306 into a Phase IIb trial with topline results expected in 2027.
Phase I data for the long-acting amylin analog, which analysts touted as encouraging, highlights AbbVie's potential diversification beyond immunology and inflammation.
Roche’s Phase III persevERA trial of giredestrant plus palbociclib in first-line ER-positive advanced breast cancer has missed its progression-free survival endpoint.